Welcome to our website...

About us...

Bionexus® develops nutritional supplements based on a product development model similar to that used by the pharmaceutical industry—but with a focus on natural ingredients. Their proprietary process applies the most recent scientific methodologies to address the management of such inflammation-based chronic illnesses as eczema, osteoarthritis, metabolic syndrome, type 2 diabetes, obesity and irritable bowel syndrome in humans and animals. With 117 peer-reviewed, scientific publications and 41 US patents, Drs. Linda M. Pacioretty and John G. Babish of Bionexus have established a reputation of strong scientific knowledge and integrity in the pharmaceutical as well as the nutritional supplement communities. Bionexus rapidly commercializes its phytochemical discoveries as dietary supplements, medical foods, and nutraceuticals with the potential of developing prescription drugs from the most bioactive candidates. The company's first marketed product, NutriVir™, was introduced in January 1998 followed by NutriVir-NSA in 2001. From 2002 through 2008, other products developed through Bionexus contract research included Kaprex®, Kaprex® AI, MetalloClear, UltraInflamX®Plus 360°, Insinase™ and UltraGlycemX® 360°.

In 2011 the Company will introduce products into the pet market through their pet division, Brookton Labs - products for moist eczema, joint support and osteoarthritis utilizing their patent-pending, nontoxic extraction processing of Nigella sativa seed. These will be the first products marketed from the Nigella sativa seed that are standardized for thymoquinone content, recognized as the most active of the phytochemicals from Nigella sativa seeds.